Geoffrey Starr, MD
Neurology · Exeter, NHNPI 1831118017
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.0% of the total across 194 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,769, 3.5 times the $512 reported in 2019.
Across 194 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$715
- Sunovion Pharmaceuticals Inc.$473
- Pfizer$454
- Teva Pharmaceuticals USA, Inc.$421
- Lundbeck LLC$338
- Biogen$235
- plus $2K from 21 others
What the payments were for
- Consulting fees$1503%
- Speaking & faculty fees$241%
- Food & beverage$4,04994%
- Education$832%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $715 |
| Sunovion Pharmaceuticals Inc. | 20 | $473 |
| Pfizer | 23 | $454 |
| Teva Pharmaceuticals USA, Inc. | 21 | $421 |
| Lundbeck LLC | 18 | $338 |
| Biogen | 6 | $235 |
| Johnson & Johnson | 2 | $217 |
| Amgen | 10 | $172 |
| Neurocrine Biosciences, Inc. | 6 | $163 |
| Biohaven Pharmaceuticals, Inc. | 7 | $146 |
| Kyowa Kirin, Inc. | 7 | $124 |
| Novartis | 6 | $121 |
| Lilly USA, LLC | 6 | $116 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $105 |
| AstraZeneca(2 entities) | 4 | $100 |
| Acadia Pharmaceuticals Inc | 5 | $81 |
| UCB, Inc. | 2 | $53 |
| Argenx US, Inc. | 2 | $49 |
| Neurelis, Inc. | 1 | $42 |
| Sanofi | 2 | $38 |
| Insightec,inc | 1 | $33 |
| Acorda Therapeutics, Inc | 1 | $24 |
| Grifols USA, LLC | 1 | $23 |
| Life Molecular Imaging Ltd | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| Impel Pharmaceuticals Inc. | 1 | $20 |
| Travere Therapeutics, Inc. | 2 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,306 in reported general payments places this provider in the 85th percentile of 92 neurology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 66 | $115,908 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 41 | $32,226 |
| Emgality PenGalcanezumab-Gnlm | 31 | $22,840 |
| Topiramate ErTopiramate | 14 | $4,908 |
| Levetiracetam | 69 | $3,374 |
| Gabapentin | 193 | $3,326 |
| Memantine Hcl | 144 | $3,244 |
| Baclofen | 44 | $3,063 |
| Memantine Hcl ErMemantine Hcl | 16 | $2,170 |
| Clonazepam | 133 | $2,127 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 81 | $2,085 |
| Sumatriptan Succinate | 25 | $2,080 |
| Zolmitriptan | 14 | $1,942 |
| Naratriptan Hcl | 27 | $1,763 |
| AmantadineAmantadine Hcl | 44 | $1,748 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $454 | $115,90866 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide | $21 | $1,32030 claims |
| Lilly USA, LLCOlanzapine | $116 | $24213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 92 neurology providers in New Hampshire.
Other neurology in Exeter
- Ann CabotManchester$622K
- Oliver PhillipsLebanon$50K
- Andrew PachnerLebanon$31K
- Jeffrey RindDerry$27K
- Uladzimir LuchanokDerry$21K
- John RescignoDerry$20K
- Jeffrey CohenLebanon$18K
- Jacob KaufmanNashua$17K
- Jianhui ZhangLebanon$12K
- Chad MeshbergerConcord$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.